| Entry |
|
|---|
| Name |
Patisiran sodium (JAN);
Onpattro (TN)
|
|---|
| Product |
|
|---|
| Formula |
C412H480N148O290P40.40Na
|
|---|
| Exact mass |
14297.2775
|
|---|
| Mol weight |
14303.5785
|
|---|
| Sequence |
RNA: auggaauacu cuugguuact t
complex with RNA: guaaccaaga guauuccaut t |
|---|
| Type |
Nucleotide |
|---|
| Remark |
| Therapeutic category: | 1290 |
| Product (DG02955): | D10794<JP/US> |
|
|---|
| Efficacy |
Gene expression regulator, Prealbumin expression inhibitor |
|---|
| Disease |
Hereditary transthyretin-mediated amyloidosis [DS: H00845] |
|---|
| Comment |
RNA interference (RNAi) drug
Treatment of hereditary ATTR amyloidosis
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07X OTHER NERVOUS SYSTEM DRUGS
N07XX Other nervous system drugs
N07XX12 Patisiran
D10794 Patisiran sodium (JAN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Patisiran
D10794 Patisiran sodium (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
12 Agents affecting peripheral nervous system
129 Miscellaneous
1290 Miscellaneous
D10794 Patisiran sodium (JAN)
Target-based classification of drugs [BR:br08310]
Transporters
Other transporters
Others
TTR
D10794 Patisiran sodium (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10794
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10794
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10794
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10794
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
